Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study was to evaluate the effect of meloxicam tablets (7.5, 15 mg
and 30 mg) with meloxicam placebo. Extended-release indomethacin capsules (75 mg) was an
active control to assess trial sensitivity on bleeding time in healthy subjects. The
secondary aim of this study was to assess effects of treatment on other platelet function and
coagulation parameters.